Solventum (NYSE:SOLV) vs. BG Medicine (OTCMKTS:BGMD) Financial Survey

Solventum (NYSE:SOLV) and BG Medicine (OTCMKTS:BGMD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and target prices for Solventum and BG Medicine, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1	6	4	0	2.27
BG Medicine	0	0	0	0	0.00

Solventum currently has a consensus price target of $84.3750, suggesting a potential upside of 15.20%. Given Solventum’s stronger consensus rating and higher probable upside, equities analysts plainly believe Solventum is more favorable than BG Medicine.

Valuation & Earnings

This table compares Solventum and BG Medicine”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.25 billion	1.54	$478.00 million	$2.16	33.91
BG Medicine	N/A	N/A	N/A	N/A	N/A

Solventum has higher revenue and earnings than BG Medicine.

Profitability

This table compares Solventum and BG Medicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solventum	4.55%	31.01%	6.53%
BG Medicine	N/A	N/A	N/A

Risk and Volatility

Solventum has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, BG Medicine has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500.

Summary

Solventum beats BG Medicine on 7 of the 8 factors compared between the two stocks.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

About BG Medicine

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.